Tresiba and Lantus are two popular long-acting insulin choices among individuals with diabetes. These medications help people control their blood glucose levels for a lengthy period of time, typically 24 hours or more. 

Diabetes is a common medical condition that affects millions of people worldwide, posing difficulties in regulating blood sugar (glucose) levels in their bodies. Insulin treatment is critical for many people with diabetes, especially those who do not produce enough insulin, the hormone that regulates blood sugar levels. While Tresiba and Lantus perform the same function, they are not identical. Knowing the differences between these two insulin options will help diabetics and their healthcare providers choose the best option for their specific needs.

In this post, we will look at the key differences between Tresiba and Lantus, including duration of action, probable adverse effects, and overall simplicity of usage.

 Background on Insulin Therapy

Insulin treatment has advanced significantly since its first discovery in the 1920s. Previously, diabetics had few options because insulin had to be sourced from animals, resulting in less consistent and difficult administration. Today, thanks to medical advances, different types of insulin are available, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins.

Long-acting insulin is used to provide insulin on a continuous basis. This suggests that it can help to keep blood sugar levels consistent throughout the day and night, which is important in diabetes management. Tresiba and Lantus are both long-acting insulins with unique characteristics that may be more appropriate for specific people.

 Tresiba and Lantus: How They Work

Before digging into the differences between Tresiba and Lantus, it’s important to understand their processes of action. Tresiba and Lantus are both types of basal insulin, which provide a steady low amount of insulin throughout the day to control blood sugar levels between meals and while sleeping.

Tresiba and Lantus work by mimicking the effects of natural insulin in the body. Following injection, they gradually and consistently release insulin, which aids in the reduction of blood sugar levels without causing sharp surges or drops. However, how these insulins are delivered into the body differs.

• Tresiba (insulin degludec) has a unique molecular structure that allows it to function for more than 24 hours. This provides a more adjustable dose schedule, potentially leading to more balanced blood sugar management.
• Lantus (insulin glargine), on the other hand, lasts about 24 hours and is often given once a day at the same time every day to keep blood sugar levels consistent.

Minor differences in their function can have a major impact on an individual’s insulin treatment and blood sugar management.

Duration of Action

One significant difference between Tresiba and Lantus is the duration of action in the body.

• long-lasting effectiveness: Tresiba is notable for its long-lasting effectiveness. It has the ability to prolong for 42 hours, resulting in continuous insulin delivery for over 48 hours. This extended action allows for more flexibility in scheduling injections, which is advantageous for people who have busy schedules or unpredictable routines.

• Lantus lasts around 24 hours: Although it may appear lengthy, shots must be administered daily at predictable times in order to maintain stable blood sugar levels. For many people, a 24-hour period is sufficient, but Lantus lacks the flexibility of Tresiba.

Tresiba’s longer time period is especially advantageous for people who struggle to stick to daily injection regimens or who prefer more flexibility in their daily routines. Nonetheless, some people may find that Lantus’ 24-hour longevity is beneficial if taken at the same time every day.

Hypoglycemia Risk

Hypoglycemia (low blood sugar) is a common side effect of insulin treatment. This can happen if insulin lowers blood sugar levels excessively. Managing the risk of hypoglycemia is an important element of administering insulin safely.

According to research, Tresiba may have a lower risk of hypoglycemia than Lantus, especially at night. Hypoglycemia at night is extremely dangerous because it might be neglected while sleeping.

• Tresiba has been shown to reduce the number of episodes of low blood sugar, making it a possible safer option for people who are more susceptible to hypoglycemia. Its constant and lengthy duration helps to avoid rapid drops in blood sugar levels.

• Lantus can help maintain blood sugar levels, but it can also raise the risk of hypoglycemia if the dose is not adjusted correctly.

Tresiba may be a better option for people who are at higher risk of hypoglycemia, especially those who experience low blood sugar levels at night. Nonetheless, it is critical to remember that the response to insulin differs from person to person, and the risk of hypoglycemia might fluctuate depending on a variety of factors such as other drugs, nutrition, and physical activity. 

Injection Pens and Convenience

Both Tresiba and Lantus are available as convenient pre-filled injectable pens; however, the pens differ in shape and properties.

• Tresiba uses the FlexTouch pen, which is designed to make injections easier and more comfortable. One notable feature is that the pen requires less force to give the insulin, which is advantageous for people who have arthritis or limited hand mobility. The FlexTouch pen has an adjustable dose dial, which makes it easier to determine the optimum insulin quantity.
• Lantus is compatible with the SoloStar pen, which is user-friendly but may require more pressure to inject. Similar to the FlexTouch pen, the SoloStar pen allows users to tailor their insulin dosage, albeit it may not provide the same level of comfort for some people.

Both pens are designed for user ease; however, persons with dexterity issues may prefer Tresiba’s FlexTouch pen. 

High-Concentration Form

Another notable difference between Tresiba and Lantus is the availability of a high-concentration variant.

• Tresiba includes a U-200 variant, which is a higher concentrated insulin. This is very useful for people who need a lot of insulin. The U-200 form allows people to administer the same quantity of insulin in a more concentrated form, which means fewer injections or less fluid per injection.
• Lantus is not available, people who require greater dosages of insulin may need to inject more liquid or take more injections.

Tresiba’s U-200 version is more convenient for patients who require high insulin levels because it reduces the number of daily injections required.

Storage and Shelf Life

Tresiba and Lantus have distinct insulin storage needs, with Tresiba having a somewhat longer shelf life.

• Tresiba can be stored at room temperature for up to 8 weeks after opening, which is longer than many other insulins, including Lantus. Individuals who travel frequently or have limited refrigeration alternatives can avoid worrying about storing their insulin in a refrigerator due to the improved period of freshness.

• Lantus, on the other hand, must be used within four weeks of opening if stored at room temperature. Although the length is adequate, it needs a higher emphasis on storage and expiration dates.

Tresiba’s extended shelf life may provide greater flexibility and peace of mind for those who travel or live in warmer climates.

Biosimilars and Unbranded Insulin

Biosimilars are medications that closely resemble branded medications but are often less expensive. Tresiba and Lantus both have generic versions, however the accessibility and possible cost savings differ.

• Lantus can be replaced with biosimilars such as Basaglar and Semglee. These biosimilars provide a more affordable option for people who need insulin but cannot afford the original brand.

There are presently no widely accessible biosimilar alternatives to Tresiba, while unbranded copies of the insulin may be available in some markets. This could result in greater prices for people who don’t have insurance or want a cheaper alternative.

If you wish to save money on insulin, Lantus biosimilars may be a better option.

 Choosing Between Tresiba and Lantus: A Guide

After comparing the main differences between Tresiba and Lantus, how do you decide which is the best option? The following are some crucial variables to consider:

• Tresiba may be a better option if you need insulin that lasts longer and allows for more variable dosing.
• If you are concerned about suffering low blood sugar levels, particularly at night, Tresiba may be a more secure option.
• If you prefer a more ergonomic pen design, Tresiba’s FlexTouch pen may be a better fit.
• If you require significant doses of insulin, Tresiba in the U-200 version may reduce the number of shots required.

• If cost is a big concern,Biosimilar versions of Lantus could be a less expensive option.

Finally, the best insulin for you will be determined by your unique needs, daily routines, and medical history. Speaking with your healthcare physician about the best option for you is critical.

 Conclusion

Tresiba and Lantus are both highly effective long-acting insulins that can help diabetics manage their blood glucose levels. Although they share many characteristics, they also differ significantly, which may lead to one being a better option depending on an individual’s personal circumstances.

Individuals with diabetes can live healthier and more adaptive lives as insulin therapy advances, thanks to new treatment options and improvements in existing drugs. Working closely with your healthcare physician is critical when choosing Tresiba, Lantus, or any other insulin to guarantee the optimum treatment plan for your specific needs.

365scriptcare.com is an established pharmacy affiliated partner. Order brand name and generic equivalent drugs online from a trusted Canadian drug source. Log onto http://www.365scriptcare.com to see how you can buy discounted drug prices shipped to the USA from Canada.